JPWO2023283049A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2023283049A5 JPWO2023283049A5 JP2024500249A JP2024500249A JPWO2023283049A5 JP WO2023283049 A5 JPWO2023283049 A5 JP WO2023283049A5 JP 2024500249 A JP2024500249 A JP 2024500249A JP 2024500249 A JP2024500249 A JP 2024500249A JP WO2023283049 A5 JPWO2023283049 A5 JP WO2023283049A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition
- sucrose
- retifanlimab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163220006P | 2021-07-09 | 2021-07-09 | |
| US63/220,006 | 2021-07-09 | ||
| PCT/US2022/034493 WO2023283049A1 (en) | 2021-07-09 | 2022-06-22 | Pharmaceutical compositions of a pd-1 antibody and use of the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024525566A JP2024525566A (ja) | 2024-07-12 |
| JP2024525566A5 JP2024525566A5 (https=) | 2025-06-30 |
| JPWO2023283049A5 true JPWO2023283049A5 (https=) | 2025-06-30 |
Family
ID=82608118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500249A Pending JP2024525566A (ja) | 2021-07-09 | 2022-06-22 | Ｐｄ‐１抗体の医薬組成物及びその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US12364756B2 (https=) |
| EP (1) | EP4366692A1 (https=) |
| JP (1) | JP2024525566A (https=) |
| KR (1) | KR20240035533A (https=) |
| CN (1) | CN118215465A (https=) |
| AR (1) | AR126404A1 (https=) |
| AU (1) | AU2022307332A1 (https=) |
| CA (1) | CA3224640A1 (https=) |
| CL (1) | CL2024000077A1 (https=) |
| CO (1) | CO2024000198A2 (https=) |
| CR (1) | CR20240065A (https=) |
| EC (1) | ECSP24008791A (https=) |
| IL (1) | IL309985A (https=) |
| MX (1) | MX2024000268A (https=) |
| PE (1) | PE20240797A1 (https=) |
| TW (1) | TW202308694A (https=) |
| WO (1) | WO2023283049A1 (https=) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1946776T (pt) * | 2002-02-27 | 2017-03-17 | Immunex Corp | Composição de tnfr-fc estabilizada compreendendo arginina |
| WO2017019846A1 (en) * | 2015-07-30 | 2017-02-02 | Macrogenics, Inc. | Pd-1-binding molecules and methods use thereof |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| US12150990B2 (en) * | 2017-11-02 | 2024-11-26 | Nanjing Shunxin Pharmaceutical Co., Ltd. | Pharmaceutical composition of humanized monoclonal anti-PD-L1 antibody |
| IL277095B2 (en) * | 2018-03-07 | 2025-10-01 | Pfizer | Preparations containing anti-PD-1 antibody |
| CN110404066B (zh) * | 2018-04-28 | 2022-06-17 | 齐鲁制药有限公司 | 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途 |
| EP4007602A1 (en) * | 2019-08-01 | 2022-06-08 | Incyte Corporation | A dosing regimen for an ido inhibitor |
| PH12022550244A1 (en) * | 2019-08-05 | 2022-12-12 | Nat Cancer Ct | Biomarkers for determining the efficacy of immune checkpoint inhibitors |
-
2022
- 2022-06-22 US US17/847,094 patent/US12364756B2/en active Active
- 2022-06-22 EP EP22744039.3A patent/EP4366692A1/en active Pending
- 2022-06-22 CA CA3224640A patent/CA3224640A1/en active Pending
- 2022-06-22 AU AU2022307332A patent/AU2022307332A1/en active Pending
- 2022-06-22 IL IL309985A patent/IL309985A/en unknown
- 2022-06-22 MX MX2024000268A patent/MX2024000268A/es unknown
- 2022-06-22 KR KR1020247004643A patent/KR20240035533A/ko active Pending
- 2022-06-22 JP JP2024500249A patent/JP2024525566A/ja active Pending
- 2022-06-22 CR CR20240065A patent/CR20240065A/es unknown
- 2022-06-22 PE PE2024000052A patent/PE20240797A1/es unknown
- 2022-06-22 WO PCT/US2022/034493 patent/WO2023283049A1/en not_active Ceased
- 2022-06-22 CN CN202280059325.XA patent/CN118215465A/zh active Pending
- 2022-07-05 TW TW111125067A patent/TW202308694A/zh unknown
- 2022-07-07 AR ARP220101785A patent/AR126404A1/es unknown
-
2024
- 2024-01-09 CL CL2024000077A patent/CL2024000077A1/es unknown
- 2024-01-11 CO CONC2024/0000198A patent/CO2024000198A2/es unknown
- 2024-02-02 EC ECSENADI20248791A patent/ECSP24008791A/es unknown
-
2025
- 2025-07-21 US US19/275,898 patent/US20250345422A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115624550B (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
| ES2899636T3 (es) | Tinostamustina para su uso en el tratamiento de cáncer de ovario | |
| JP2014132009A5 (https=) | ||
| JP2012500180A5 (https=) | ||
| ES2959952T3 (es) | Compuestos para el tratamiento del CMTN | |
| JP2006503919A5 (https=) | ||
| JP2020527139A5 (https=) | ||
| ES2946472T3 (es) | Agente antitumoral y potenciador del efecto antitumoral | |
| CN110730663B (zh) | 阿帕替尼和c-Met抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| WO2019072220A1 (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2023542093A (ja) | 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用 | |
| JP2003533485A5 (https=) | ||
| JP2015531367A (ja) | ベリノスタットおよびトラベクテジンを用いる併用療法 | |
| CA3100867A1 (en) | Use of cdk4/6 inhibitor in combination with egfr inhibitor in the preparation of medicament for treating tumor diseases | |
| TW201811323A (zh) | 抗腫瘤劑、抗腫瘤效果增強劑及抗腫瘤用套組 | |
| TW201141473A (en) | Combination therapy for small cell lung cancer | |
| JP2014510047A5 (https=) | ||
| WO2020236667A1 (en) | Methods of treating cancer | |
| CN108025190A (zh) | T-dm1难治性癌症患者的syd985治疗 | |
| CN110522753A (zh) | 一种新型抗肿瘤药物组合物、制剂和应用 | |
| ES2889900T3 (es) | Combinación de anticuerpo anti-FGFR4 y secuestrante de ácidos biliares | |
| JPWO2023283049A5 (https=) | ||
| JP2022542725A (ja) | 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用 | |
| TW201628608A (zh) | 治療或緩解高齡或末期癌症患者用之醫藥組合物 | |
| Hurwitz et al. | Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report |